Outcome of the pediatric medulloblastoma patients: Single center experience from Saudi Arabia

Abrar Aljunaid, Ahmed Ameen, Ali Alharbi, Mohammed Bayoumy, Hassan Altrabolsi and Ibraheem Abosoudah
King Faisal Specialist Hospital and Research Center, KSA

Abstract

Propose: Retrospective study reviewing the outcomes of pediatric patients with medulloblastoma.

Patients & Methods: Relevant clinical data were collected from medical charts of 41 cases of pediatric medulloblastoma patients (≤15 years) diagnosed between January 2001 and December 2017, survival analysis and prognostic factor were done.

Results: The obtained results of OS of 73.7% for the whole cohort. The lower age (Age ≤3), high risk, positive metastasis at presentation, partial resection remained vital and contributed to lower overall survival rate among the patients with P value as follow: (P: <0.001, P: 0.041, P: 0.020, P: 0.006). Moreover, event free survival rate was 54.8% for the whole cohort and analysis of it suggested that the extent of complete surgical resection (P<0.018) and age >3 years (P<0.001) was the major factor for better survival.

Conclusion: In our series, the estimated outcome of total cohort was OS 73.7% and EFS 54.8% which are comparable to the developed countries outcome. The age of >3 years and the complete surgical excision are emerging as the most significant factors affecting OS (80.5%, 88.7%) and EFS (61.2%, 70%). Average risk and negative metastasis had significant OS with p value of <0.04, <0.02 respectively. This study provides an important clue in understanding the importance of the demographic, clinical and treatment modalities in understanding the prognosis of medulloblastoma. This report will serve as an important resource from Kingdom of Saudi Arabia regarding medulloblastoma survival.

Biography:

Abrar Aljunaid has completed Bachelor of Surgery and Medicine from King Abdulaziz University in 2013 and her Pediatric Residency in 2016 from King Abdulaziz University Hospital. Later she graduated from Pediatric Hematology/Oncology Fellowship program in April 2020. She is interested in neuro/oncology in particular.


Abstract Citation: